Instil Bio Inc. (TIL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Instil Bio Inc. (TIL) has a cash flow conversion efficiency ratio of -0.012x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.34 Million) by net assets ($110.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Instil Bio Inc. market capitalisation for the company's overall valuation and market capitalisation.
Instil Bio Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Instil Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Instil Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Instil Bio Inc. ranked by their cash flow conversion efficiency. See how well can Instil Bio Inc. service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Indo Thai Securities Limited
NSE:INDOTHAI
|
0.032x |
|
Black Hawk Acquisition Corporation
NASDAQ:BKHA
|
-0.012x |
|
Cenit Co. Ltd
KQ:037760
|
-0.013x |
|
Thai Agro Energy Public Company Limited
BK:TAE
|
0.128x |
|
YES24 Co.Ltd
KQ:053280
|
0.014x |
|
Riverview Rubber Estates Bhd
KLSE:2542
|
0.009x |
|
Unick Corporation
KQ:011320
|
0.105x |
|
Texas Community Bancshares Inc
NASDAQ:TCBS
|
0.641x |
Annual Cash Flow Conversion Efficiency for Instil Bio Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Instil Bio Inc. from 2019 to 2025. View Instil Bio Inc. stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $113.87 Million | $-36.62 Million | -0.322x | +2.17% |
| 2024-12-31 | $169.44 Million | $-55.70 Million | -0.329x | +9.50% |
| 2023-12-31 | $225.83 Million | $-82.03 Million | -0.363x | +26.69% |
| 2022-12-31 | $363.61 Million | $-180.16 Million | -0.495x | -125.24% |
| 2021-12-31 | $555.20 Million | $-122.14 Million | -0.220x | -117.17% |
| 2020-12-31 | $292.37 Million | $-29.62 Million | -0.101x | +84.58% |
| 2019-12-31 | $8.06 Million | $-5.29 Million | -0.657x | -- |
About Instil Bio Inc.
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.